Saxenda vs Wegovy: Daily Shot vs Weekly Injection Compared
Medically reviewed by Medical Advisory Board Last reviewed 2026-08-03
Both are FDA-approved for weight loss — an older daily GLP-1 vs the newer, stronger weekly one
Saxenda (liraglutide) and Wegovy (semaglutide) are both FDA-approved GLP-1 injections for chronic weight management, but Saxenda is a daily shot from an older drug generation while Wegovy is a once-weekly injection that produces roughly twice the average weight loss in trials. Saxenda has a longer track record; Wegovy is the stronger, more convenient, and now more commonly prescribed option.
This article is for informational purposes only and is not medical advice. Consult a physician before starting or switching a weight-loss medication.
Saxenda and Wegovy are both made by Novo Nordisk and both target the GLP-1 receptor, but they're different molecules from different drug generations. Saxenda is liraglutide, approved for chronic weight management in 2014 and injected once daily. Wegovy is semaglutide, approved in 2021 and injected once weekly — a newer, longer-acting GLP-1 that produces substantially more weight loss in head-to-head trial data.
Want expert help with your metabolic health?
We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →For the diabetes-branded version of the same semaglutide molecule, see our Ozempic vs Wegovy comparison. For the full GLP-1 drug class picture, visit our GLP-1 guide.
Saxenda vs Wegovy: Side-by-Side
| Factor | Saxenda (liraglutide) | Wegovy (semaglutide) |
|---|---|---|
| Active ingredient | Liraglutide | Semaglutide |
| Injection frequency | Once daily | Once weekly |
| FDA approval (obesity) | December 2014 | June 2021 |
| Average weight loss (pivotal trial) | ~8% (SCALE trial, 56 weeks) | ~14.9% (STEP-1, 68 weeks) |
| Cardiovascular outcomes data | Limited dedicated CV outcomes trial for the weight-loss dose | SELECT (2023) — 20% reduction in major cardiovascular events |
| List price | ~$1,300-$1,400/month | ~$1,349/month |
| Years on the market | 10+ years — longest real-world safety record of any GLP-1 | 4+ years — shorter track record, faster-growing evidence base |
Why Wegovy Produces More Weight Loss
Semaglutide binds the GLP-1 receptor more selectively and lasts far longer in the body than liraglutide, which is why Wegovy needs only a weekly injection while Saxenda needs a daily one — and why the weight-loss numbers diverge so much. In their respective pivotal trials, Wegovy produced roughly 14.9% average weight loss over 68 weeks versus Saxenda's roughly 8% over 56 weeks, and a 2021 head-to-head trial (STEP 8) that directly compared semaglutide 2.4 mg to liraglutide 3.0 mg in the same study population found semaglutide produced significantly greater weight loss with a similar overall tolerability profile.
That gap is the main reason most obesity-medicine prescribers now start treatment-naive patients on semaglutide (Wegovy) or tirzepatide (Zepbound) rather than liraglutide (Saxenda), reserving Saxenda mainly for patients who specifically need or prefer an older, more established drug — including some adolescent and pre-existing-liraglutide-tolerant patients.
The Daily-vs-Weekly Trade-Off
Saxenda's once-daily dosing is a real practical downside for most people: it means carrying refrigerated pens more often, remembering an injection every single day, and more frequent injection-site reactions simply from more total injections. Wegovy's once-weekly schedule is easier to build into a routine and easier to travel with.
The one place daily dosing has an edge is dose flexibility during titration or a temporary pause — a missed daily dose has a smaller impact on steady-state drug levels than a missed weekly dose does, since liraglutide's half-life is much shorter than semaglutide's. In practice, this rarely outweighs the convenience and stronger efficacy of weekly dosing for most people choosing between the two today.
Track Record and Who Each One Suits
Saxenda's biggest advantage is time on the market — over a decade of real-world prescribing data, including specific pediatric obesity approval (ages 12+) that Wegovy has also since received, but with longer post-marketing surveillance behind it. For someone who wants the most-studied option, or who has already tolerated liraglutide well for diabetes (Victoza, the same molecule) and wants to stay on a familiar drug, Saxenda remains a reasonable choice.
For most people newly starting a GLP-1 for weight loss, Wegovy's stronger average results, weekly convenience, and the added cardiovascular-risk-reduction evidence from the SELECT trial make it the more commonly recommended starting point today, especially for anyone with existing cardiovascular disease. Insurance coverage, not clinical preference, is often the deciding factor in practice — check your plan's formulary for both before assuming either is out of reach.
The Verdict
Wegovy produces more weight loss with a more convenient schedule; Saxenda has the longer track record. If you're starting fresh and your insurance covers both, Wegovy's stronger trial data and weekly dosing make it the more commonly recommended choice today. Saxenda remains a reasonable option if you've already tolerated liraglutide well, need the pediatric-specific approval history, or your coverage specifically favors it. Both require a prescription and medical supervision. Take our free assessment or book a consultation to work through which fits your history.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.
Frequently Asked Questions
Is Wegovy better than Saxenda for weight loss?
In head-to-head and pivotal trial data, Wegovy (semaglutide) produces more average weight loss than Saxenda (liraglutide) — roughly 14.9% versus 8% in their respective 56-68 week trials. A direct comparison trial (STEP 8) found semaglutide produced significantly greater weight loss than liraglutide with a similar tolerability profile.
Why is Saxenda a daily injection while Wegovy is weekly?
Saxenda's active ingredient, liraglutide, has a shorter half-life in the body than Wegovy's active ingredient, semaglutide, which is chemically modified to stay active far longer. That difference is why liraglutide requires daily dosing to maintain steady drug levels, while semaglutide only needs one injection per week.
Which has fewer side effects, Saxenda or Wegovy?
Both cause similar gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation, mostly during dose escalation — and share the same class warnings, including a boxed warning about thyroid C-cell tumors seen in animal studies. Head-to-head trial data shows broadly comparable overall tolerability between the two, though individual response varies.
Can I switch from Saxenda to Wegovy?
Yes, with medical guidance. Many patients who started on Saxenda before Wegovy's approval have since switched to semaglutide for its stronger results and weekly convenience. A clinician typically stops liraglutide and starts semaglutide at a low titration dose rather than an equivalent-strength dose, to manage GI side effects during the transition.
Is Saxenda or Wegovy covered better by insurance?
Coverage varies significantly by plan and isn't consistently better for either drug. Some formularies favor the newer semaglutide-based products (Wegovy); others still cover Saxenda more readily, especially for patients already established on liraglutide. Checking your specific plan's formulary, and any manufacturer savings program, is the only reliable way to know which costs less for you.
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Continue Reading
-
What Is Insulin Resistance? Causes, Symptoms & How to Reverse It
What insulin resistance is, how to test for it, and how to reverse it.
-
Hyperinsulinemia
Chronically high insulin: symptoms, causes, how it differs from insulin resistance, and how to reverse it.
-
Metabolic Syndrome — Diagnosis, Risks, and Treatment
The five diagnostic criteria and what they mean for your health.
-
Insulin Resistance Symptoms: 12 Warning Signs
12 clinical warning signs, from acanthosis nigricans to post-meal fatigue.
-
Blood Sugar Crash: Why It Happens and How to Stop It
Reactive hypoglycemia: causes, symptoms, and how to stabilize glucose.
-
Glucose Spikes After Eating: Causes and What to Do
Why blood sugar spikes after eating and what to do about it.
-
Fatigue After Eating: Why Food Makes You Tired
Post-meal fatigue explained — insulin, glucose, and the gut-brain axis.
-
Hypoglycemia Symptoms: Low Blood Sugar Warning Signs
Low blood sugar warning signs and when to seek medical attention.
-
How to Reverse Insulin Resistance Naturally
Evidence-based dietary and lifestyle interventions (3-16 week timeline).
-
Slow Metabolism: Myths, Causes, and What Actually Works
Why metabolism slows, what's myth vs reality, and what the evidence says.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.